-
Funds will support progression of Aro’s pipeline of Centyrin-siRNA programs, including ABX1100, a novel potential treatment for Pompe Disease.
-
Christopher Picariello, President, Johnson & Johnson Innovation – JJDC, Inc. named to Board of Directors.
Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, announced it has secured $41.5M in a Series B funding round. The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P. In conjunction with the financing, Christopher Picariello, President, JJDC, has joined Aro’s Board of Directors.
Fintech Insights: Three Game-changing Examples of AI in Private Equity
“We are appreciative of the support provided by this syndicate of leading life science industry investors,” said Susan Dillon, Ph.D., Chief Executive Officer of Aro. “Aro is well positioned to advance our pipeline and progress the field by leveraging our Centyrin platform to enable efficient and tissue-targeted delivery of siRNA. This funding enables us to continue to pursue our mission and bring new medicines to patients who desperately need more effective treatments.”
Aro will use the funds to advance development of its lead program, ABX1100, a novel potential treatment for patients with Pompe Disease. Aro recently announced the start of a first-in-human with ABX1100, and the Company anticipates that initial data from this study will be presented in 2024. In addition, the Series B funding will support new Centyrin-siRNA conjugate programs focused on the discovery of new therapies for autoimmune disorders.
Read More About Fintech Interview: Global Fintech Interview with Alessandro Onano, CMO at Tymit
[To share your insights with us, please write to pghosh@itechseries.com ]
